Letter

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Study conclusions do not reflect findings for celecoxib

BMJ 2005; 331 doi: 10.1136/bmj.331.7530.1473-d (Published 15 December 2005)
Cite this as: BMJ 2005;331:1473.5

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Joe Feczko, chief medical officer (rscmoppgp-JoeFeczko@pfizer.com)
  1. Pfizer, New York, NY 10017, USA

    EDITOR—The conclusions drawn by Hippisley-Cox et al do not accurately reflect the data as presented.1

    This study found important differences between celecoxib and the studied non-steroidal anti-inflammatory drugs (NSAIDs) in terms of the risk of adverse gastrointestinal effects. Specifically, celecoxib was the only treatment that did …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular